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Abstract
Background:  To balance the cardiovascular benefits from low-dose aspirin against the
gastrointestinal harm caused, studies have considered the coronary heart disease risk for each
individual but not their gastrointestinal risk profile. We characterized the gastrointestinal risk
profile of low-dose aspirin users in real clinical practice, and estimated the excess risk of upper
gastrointestinal complications attributable to aspirin among patients with different gastrointestinal
risk profiles.
Methods:  To characterize aspirin users in terms of major gastrointestinal risk factors (i.e.,
advanced age, male sex, prior ulcer history and use of non-steroidal anti-inflammatory drugs), we
used The General Practice Research Database in the United Kingdom and the Base de Datos para
la Investigación Farmacoepidemiológica en Atención Primaria in Spain. To estimate the baseline risk
of upper gastrointestinal complications according to major gastrointestinal risk factors and the
excess risk attributable to aspirin within levels of these factors, we used previously published meta-
analyses on both absolute and relative risks of upper gastrointestinal complications.
Results: Over 60% of aspirin users are above 60 years of age, 4 to 6% have a recent history of
peptic ulcers and over 13% use other non-steroidal anti-inflammatory drugs. The estimated average
excess risk of upper gastrointestinal complications attributable to aspirin is around 5 extra cases
per 1,000 aspirin users per year. However, the excess risk varies in parallel to the underlying
gastrointestinal risk and might be above 10 extra cases per 1,000 person-years in over 10% of
aspirin users.
Conclusion: In addition to the cardiovascular risk, the underlying gastrointestinal risk factors have
to be considered when balancing harms and benefits of aspirin use for an individual patient. The
gastrointestinal harms may offset the cardiovascular benefits in certain groups of patients where
the gastrointestinal risk is high and the cardiovascular risk is low.
Background
Cardiovascular disease is the leading cause of morbidity
and mortality in Europe and North America [1]. The over-
all incidence of myocardial infarction is around 1 to 3
cases per 1,000 person-years [1,2]. However, a given per-
son's risk for myocardial infarction varies significantly
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with a number of factors including age, sex, blood pres-
sure, cigarette smoking, diabetes, cholesterol levels, and a
previous diagnosis of cardiovascular disease [3]. This risk
variability is so widely accepted that the specific cardio-
vascular risk for a given person can be formally estimated
using equations currently available on the web [4].
Long-term use of low-dose aspirin reduces the risk of
myocardial infarction by about 25%–30% irrespective of
the baseline risk [5-7], therefore this relative change has a
greater absolute impact on persons with an elevated
underlying risk. It has been estimated that treating
patients with a moderately high baseline risk with aspirin
would prevent up to 4 myocardial infarctions per 1,000
persons treated per year, while treating low risk patients
would prevent less than 1 event per 1,000 persons treated
per year [8].
The cardiovascular benefits from low-dose aspirin have to
be balanced against the potential gastrointestinal harm.
Observational studies have estimated that the incidence
of serious upper gastrointestinal tract complications
(UGIC; i.e., bleeding or perforation) in the general popu-
lation is on the order of 1 case per 1,000 person-years,
with a case fatality rate around 5–10% [9]. Aspirin use,
even at doses below 300 mg/day and despite modified
release formulations, has been associated with a two to
threefold increased risk of developing UGIC [10]. Based
on these data, the average incidence of UGIC would be
close to 2–3 cases per 1,000 person-years for aspirin users,
and about 1–2 of these cases might be attributable to aspi-
rin. Clinical trials, typically conducted in low-risk sub-
jects, have also estimated an overall excess of 1–2 cases of
UGIC per 1,000 patients treated with aspirin per year [8].
After considering the absolute increase in bleeding com-
plications associated with aspirin, several studies have
suggested that aspirin use for prevention of cardiovascular
events might be harmful for groups of patients at low risk
for coronary heart disease (< 5 events per 1,000 person-
years) and clearly beneficial for high-risk groups (≥15
events per 1,000 person-years) [3,11,12]. While these
studies considered various cardiovascular risk factors to
determine the coronary heart disease risk for each individ-
ual, they did not take into account the independent gas-
trointestinal risk factors to determine individualized
UGIC risks.
Estimates of the specific UGIC risk for each person would
add a valuable piece of information to individual thera-
peutic decisions and could optimize the overall risk-ben-
efit profile of aspirin. Therefore, we describe below i) the
distribution of the main risk factors for UGIC among pop-
ulations of prescription aspirin users, ii) the estimated
baseline risk of UGIC within levels of these factors, and
iii) the estimated excess risk of UGIC that could be attrib-
uted to aspirin within subgroups of aspirin users with spe-
cific baseline risks of UGIC.
Methods
Distribution of major risk factors
To describe the distribution of major gastrointestinal risk
factors among aspirin users, we used two different sources
of data:
The General Practice Research Database (GPRD)
The GPRD is a population-based database in the United
Kingdom where general practitioners retrieve and store on
computer clinical information on their patients, including
demographics, diagnoses and comments, referral infor-
mation and records of all prescriptions issued by them, as
well as their dose and indication [13]. All these data are
automatically and continuously passed on to the GPRD.
Data on about 3 million patients are systematically
recorded and sent anonymously to the Medicines and
Healthcare products Regulatory Agency. This agency col-
lects and organizes this information in order for it to be
used for research projects. The Read classification system
is used to code specific diagnoses, and a drug dictionary
based on data from the Prescription Pricing Authority is
used to code drugs. The accuracy and completeness of
these data have been validated in previous studies [14,15].
The source population for the current study encompassed
a cohort of patients aged 20 to 99 years in the year 2000
who had been enrolled for at least two years with the GP.
For each patient, we selected a random date during 2000
as the index date and considered this date as a snapshot of
the population. We defined patients as "aspirin users"
when the supply of a prescription for aspirin lasted until
the index date or ended within the period of 3 months
before index date (N = 16,598). Within aspirin users, the
following characteristics were studied as important risk
factors for UGIC: history of upper gastrointestinal disor-
der while enrolled in the database (dyspepsia, peptic
ulcer, upper gastrointestinal bleeding/perforation), sex,
age, and current or recent use of non-aspirin non-steroidal
anti-inflammatory drugs (NSAIDs) by the index date (i.e.,
prescription lasted until the index date or ended within
the 3 months before).
Base de Datos para la Investigación Farmacoepidemiológica en 
Atención Primaria (BIFAP)
BIFAP is a population-based database in Spain where gen-
eral practitioners retrieve and store on computer clinical
information on their patients including demographics,
diagnoses and comments, referral information and
records of all prescriptions issued by them [16]. All this
information is automatically and periodically passed on
to BIFAP. Data on an excess of 1 million patients is sys-BMC Medicine 2006, 4:22 http://www.biomedcentral.com/1741-7015/4/22
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tematically recorded and sent anonymously to the Span-
ish Medicines Agency. This agency collects and organizes
the information. The ICPC classification system is used to
code specific diagnoses, and the National Dictionary of
Drugs is used to code drugs. This database is currently in
its pilot phase and the accuracy and completeness of the
data source is being examined [17].
The source population for the current study encompassed
a cohort of patients aged 20 to 99 years in the year 2000.
We selected a random date during 2000 as the index date
and consider this date as a snapshot of the population. We
defined patients as "aspirin users" when the supply of a
prescription for aspirin lasted until the index date or
ended within the period of 3 months before index date (N
= 9,129). We classified aspirin users according to the indi-
cation for aspirin. Within patients treated with aspirin for
cardioprotection, the following characteristics were stud-
ied as important risk factors for UGIC: history of upper
gastrointestinal disorder, sex, age, and current or recent
use of NSAIDs by the index date (i.e., prescription lasted
until the index date or ended within the 3 months before).
Specific risks and excess risks
To estimate the baseline incidence rate of UGIC according
to major gastrointestinal risk factors and the excess risk of
UGIC that could be attributed to aspirin within levels of
these factors, we analyzed data from the GPRD and con-
ducted systematic reviews of the literature.
The General Practice Research Database (GPRD)
Original analyses from the GPRD have been already pub-
lished [18,19]. Briefly, the source population encom-
passed patients aged 40 to 79 years between April 1993 to
October 1998, with at least 2 years' enrollment in the
database. We identified incident cases of UGIC that were
referred to a specialist or admitted to a hospital. Controls
frequency-matched for age, sex and calendar year were
selected randomly from the person-time at risk of the
source population. The index date was the date of the first
diagnosis for cases and a random date for controls. We
defined patients as "current users" of aspirin or NSAIDs
when the supply of a prescription lasted until the index
date or ended within a window of 30 days before the
index date. Non-users were those with no prescription
ever recorded before the index date. Adjusted estimates of
relative risk associated with the current use of aspirin and
NSAIDs compared to non-use, as well as the effects and
the potential interaction with other risk factors were stud-
ied using unconditional logistic regression.
Systematic reviews of the literature
We have conducted and published systematic reviews on
both absolute and relative risks of UGIC, which included
our own estimates from the GPRD [9,10,20]. The studies
included in these meta-analyses defined UGIC as bleed-
ing, perforation, or other serious upper gastrointestinal
tract event resulting in hospitalization or visit to a special-
ist. The literature suggests that the major risk factors for
the development of UGIC are being aged over 60, male
gender, history of peptic ulcer, and concomitant use of
NSAIDs. All the estimates mentioned below are based on
pooled relative risks (RR) from meta-analyses and have
very tight confidence intervals. For example, the pooled
RR was 2.5 (95% CI: 2.4, 2.7) for aspirin overall and 2.0
(95% CI: 1.7–2.2) for doses up to 300 mg/day.
Risk, relative risk, and excess risk estimates
To estimate absolute incidence rates within each risk sub-
group, and based on pooled estimates from ours and oth-
ers' original studies, [9,10,20] we assumed the following:
i) The overall baseline UGIC incidence rate is in the order
of 1 per 1,000 person-years (pooled incidence rate = 0.99;
95%CI 0.84–1.18). ii) The incidence increases exponen-
tially with age, from less than 1 per 1,000 person-years
until the age of 60 to over 5 per 1,000 person-years at age
85 years. iii) Within age groups, the incidence rates among
men are double those among women. iv) Regarding pre-
vious ulcer history, the relative risks used for past upper
gastrointestinal pain/dyspepsia, uncomplicated and com-
plicated ulcers were 2, 6, and 10, respectively. v) The rela-
tive risk associated with NSAIDs has been shown to be
lower among patients with past ulcer history, even though
the absolute risk is still higher among NSAID users with
ulcer history. Briefly, exposure to NSAIDs causes over a
fourfold increase in the risk of UGIC for patients without
prior history (from 1 to 4 cases per 1,000 persons per
year), and a greater than twofold increase in patients with
a history of peptic ulcer disease (from 10 to 25 cases per
1,000 persons per year). Hence, the effect of NSAIDs on
the risk of UGIC decreases proportionally with the sever-
ity of the prior gastrointestinal condition. However,
patients with a history of complicated ulcer disease
present the greatest absolute risk of UGIC when taking
NSAIDs, that is, about 25 cases per 1,000 person-years,
from which 15 cases could be attributable to NSAID treat-
ment. The relative risks used for NSAID use were 2.5 in
subjects with a past history of complicated or uncompli-
cated ulcer, 3 in subjects with past upper gastrointestinal
pain, and 4 in subjects with no previous upper gastroin-
testinal complaint. vi) Low-dose aspirin doubles the risk
of UGIC in each of these risk groups.
The difference in UGIC rates between aspirin users and
non-users within levels of major risk factors was consid-
ered as excess risk attributable to aspirin use (i.e., we
assumed no residual confounding). To evaluate the sensi-
tivity of the results to our assumptions, we repeated the
analyses for a range of plausible values for each estimate.
The sensitivity analysis for the effect of aspirin on UGIC,BMC Medicine 2006, 4:22 http://www.biomedcentral.com/1741-7015/4/22
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for which RRs of 1.5, 2, and 3 were considered, is pre-
sented here. To validate our calculations, we applied our
UGIC risk estimations to the populations of patients
included in the control groups of recent clinical trials [21-
23], and compared our estimates with the UGIC risks
reported in these studies.
Results
The prevalence of prescription aspirin use was 4.6% in the
GPRD and 3.4% in BIFAP. Over 95% of the aspirin use
recorded in the GPRD and 59% of the use in BIFAP was
for cardioprotection. In both data sources the prevalence
of aspirin use increased substantially with age (Figure 1).
The distribution of gastrointestinal risk factors among car-
dioprotection aspirin users is presented in Figure 2. Over-
all, the proportion of aspirin users above 60 years of age
was 88% in the GPRD and 79% in BIFAP. The proportion
of males was 52% in the GPRD and 54% in BIFAP. The
proportion of aspirin users with a recorded history of gas-
trointestinal ulcer was 3.8% in the GPRD and 5.9% in
BIFAP. The proportion of aspirin users with a recorded
past episode of UGIC was 1.2% in the GPRD and 1.9% in
BIFAP. The proportion of aspirin users concomitantly
using NSAIDs was 14.8% in the GPRD and 13.2% in
BIFAP. NSAID use was not included in the figure to sim-
plify the presentation.
Figure 3 depicts how the estimated incidence rate of UGIC
increases with age and with past history of ulcer both for
males and females. These rates would be around four
times higher among NSAID users and would double with
aspirin use. Taking into account the distribution of base-
line gastrointestinal risk factors among aspirin users in
each population, the estimated average incidence rate of
UGIC among aspirin users was 12 cases per 1,000 person-
years in the GPRD and 10 in the BIFAP. However, this rate
can be more than 20 cases per 1,000 person-years in cer-
tain high-risk groups. For example, considering, age, sex,
ulcer history and use of NSAIDs as stratifying factors, the
expected UGIC incidence rate would be above 20 per
1,000 person-years in 14% and 11% of aspirin users,
based on GPRD and BIFAP, respectively. Moreover, in a
smaller fraction of the population, for example males 70
and older with a recent history of peptic ulcer and who
take aspirin and NSAIDs concomitantly, the risk might
exceed 100 cases per 1,000 person-years.
The number of cases that could be attributable to aspirin
among aspirin users according to age, sex, and ulcer his-
tory is also presented in Figure 3. For cardioprotection
aspirin users overall, the estimated excess risk of UGIC
was 6 and 5 cases per 1,000 users per year in the GPRD
and BIFAP, respectively. These figures would be larger in
high-risk groups. For example, patients with baseline inci-
dence rates over 20 per 1,000 person-years, such as males
70 years and older with a past history of uncomplicated
peptic ulcer, would develop over 40 cases per 1,000 per-
son-years if they were treated with low-dose aspirin; thus,
more than 20 cases per 1,000 aspirin users with these risk
Prevalence of aspirin use for cardioprotection in the UK (General Practice Research Database; GPRD) and Spain (Base de  Datos para la Investigación Farmacoepidemiológica en Atención Primaria; BIFAP) by age for females and males Figure 1
Prevalence of aspirin use for cardioprotection in the UK (General Practice Research Database; GPRD) and Spain (Base de 
Datos para la Investigación Farmacoepidemiológica en Atención Primaria; BIFAP) by age for females and males.
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factors per year could be attributable to their use of aspi-
rin.
The number of extra cases attributable to aspirin depends
on the assumptions regarding incidence rates, distribu-
tion of risk factors, and relative risks used throughout the
analyses. Estimates were particularly sensitive to the value
used for the relative risk of UGIC associated with aspirin
use. Figure 4 presents the number of extra cases poten-
tially attributable to aspirin according to age, sex, and
ulcer history for a plausible range of relative risks associ-
ated with low-dose aspirin (i.e., from 1.5 to 3).
Based on our estimates, the expected incidence of UGIC in
the control groups of the Vioxx Gastrointestinal Out-
comes Research (VIGOR) trial [21], the Celecoxib Long-
term Arthritis Safety Study (CLASS) [22], and the Thera-
peutic Arthritis Research and Gastrointestinal Event Trial
(TARGET) [23] would have been 7, 9.5 and 8.1 cases per
1,000 person-years, respectively; the actual reported
annualized rates were 8.6, 14.5, and 9.1 per 1,000 person-
years, respectively (Table 1).
Discussion
The prevalence of cardioprotective aspirin use among
adults in year 2000 was 4.6% in the UK and 2.0% in Spain
Estimated incidence rate of upper gastrointestinal tract com- plications (UGIC) per 1,000 person-years and estimated  excess number of cases per 1,000 cardioprotection aspirin  users per year attributable to aspirin within levels of gas- trointestinal risk factors Figure 3
Estimated incidence rate of upper gastrointestinal tract com-
plications (UGIC) per 1,000 person-years and estimated 
excess number of cases per 1,000 cardioprotection aspirin 
users per year attributable to aspirin within levels of gas-
trointestinal risk factors.
FACTORS Incidence rate
Age Sex Prior history NSAIDs ASPIRIN USE
Excess number of 
UGIC cases
No Yes
None No 0.4 0.8 0.4
Yes 1.6 3.2 1.6
upper GI pain No 0.8 1.6 0.8
Female Yes 3.2 6.4 3.2
uncomplicated ulcer No 2.4 4.8 2.4
Yes 7.2 14.4 7.2
complicated ulcer  No 4.0 8.0 4
Yes 10.0 20.0 10
20-60
None No 0.8 1.6 0.8
Yes 3.2 6.4 3.2
upper GI pain No 1.6 3.2 1.6
Male Yes 6.4 12.8 6.4
uncomplicated ulcer No 4.8 9.6 4.8
Yes 14.4 28.8 14.4
complicated ulcer  No 8.0 16.0 8
Yes 20.0 40.0 20
None No 1.2 2.4 1.2
Yes 4.8 9.6 4.8
upper GI pain No 2.4 4.8 2.4
Female Yes 9.6 19.2 9.6
uncomplicated ulcer No 7.2 14.4 7.2
Yes 21.6 43.2 21.6
complicated ulcer  No 12.0 24.0 12
Yes 30.0 60.0 30
60-69
None No 2.4 4.8 2.4
Yes 9.6 19.2 9.6
upper GI pain No 4.8 9.6 4.8
Male Yes 19.2 38.4 19.2
uncomplicated ulcer No 14.4 28.8 14.4
Yes 43.2 86.4 43.2
complicated ulcer  No 24.0 48.0 24
Yes 60.0 120.0 60
None No 1.8 3.6 1.8
Yes 7.2 14.4 7.2
upper GI pain No 3.6 7.2 3.6
Female Yes 14.4 28.8 14.4
uncomplicated ulcer No 10.8 21.6 10.8
Yes 32.4 64.8 32.4
complicated ulcer  No 18.0 36.0 18
Yes 45.0 90.0 45
70-79
None No 3.6 7.2 3.6
Yes 14.4 28.8 14.4
upper GI pain No 7.2 14.4 7.2
Male Yes 28.8 57.6 28.8
uncomplicated ulcer No 21.6 43.2 21.6
Yes 64.8 129.6 64.8
complicated ulcer  No 36.0 72.0 36
Yes 90.0 180.0 90
None No 3.0 6.0 3
Yes 12.0 24.0 12
upper GI pain No 6.0 12.0 6
Female Yes 24.0 48.0 24
uncomplicated ulcer No 18.0 36.0 18
Yes 54.0 108.0 54
complicated ulcer  No 30.0 60.0 30
Yes 75.0 150.0 75
>=80
None No 6.0 12.0 6
Yes 24.0 48.0 24
upper GI pain No 12.0 24.0 12
Male Yes 48.0 96.0 48
uncomplicated ulcer No 36.0 72.0 36
Yes 108.0 216.0 108
Complicated ulcer  No 60.0 120.0 60
Yes 150.0 300.0 150
Distribution of risk factors for upper gastrointestinal tract  complications (UGIC) among cardioprotective aspirin users  in the UK (General Practice Research Database; GPRD) and  Spain (Base de Datos para la Investigación Farmacoepidemi- ológica en Atención Primaria; BIFAP) Figure 2
Distribution of risk factors for upper gastrointestinal tract 
complications (UGIC) among cardioprotective aspirin users 
in the UK (General Practice Research Database; GPRD) and 
Spain (Base de Datos para la Investigación Farmacoepidemi-
ológica en Atención Primaria; BIFAP).
FACTORS  % of subjects in each subgroup 
Age Sex Prior history  GPRD BIFAP
None 0.78  1.63 
upper GI pain  0.54  0.26 
Female uncomplicated  ulcer  0.03  0.03 
complicated ulcer   0.02  0.02 
20-49    
None 1.18  3.20 
upper GI pain  0.62  0.37 
Male uncomplicated  ulcer  0.04  0.11 
complicated ulcer   0.01  0.04 
  
   None  1.81  3.45 
   upper GI pain  1.30  0.79 
Female uncomplicated  ulcer  0.02  0.05 
complicated ulcer   0.03  0.02 
50-59    
None 3.57  8.51 
upper GI pain  1.84  1.53 
Male uncomplicated  ulcer  0.15  0.48 
complicated ulcer   0.05  0.20 
  
None 6.01    6.58 
   upper GI pain  3.74   1.92 
Female  uncomplicated ulcer  0.20   0.18 
complicated ulcer   0.06  0.11 
60-69    
None 9.94    11.26 
upper GI pain  5.01   2.43 
Male  uncomplicated ulcer  0.57   0.91 
complicated ulcer   0.18  0.24 
  
   None  10.13  11.95 
   upper GI pain  6.27  3.67 
Female uncomplicated  ulcer  0.34  0.44 
complicated ulcer   0.12  0.26 
70-79    
None 11.77  12.32 
upper GI pain  6.26  2.69 
Male uncomplicated  ulcer  0.67  1.19 
complicated ulcer   0.27  0.42 
  
   None  10.97  11.95 
   upper GI pain  5.40  1.90 
Female uncomplicated  ulcer  0.34  0.22 
complicated ulcer   0.19  0.26 
>=80   
   None  5.94  6.45 
   upper GI pain  3.14  1.35 
Male uncomplicated  ulcer  0.23  0.35 
Complicated ulcer   0.25  0.35 
TOTAL  100%  100% BMC Medicine 2006, 4:22 http://www.biomedcentral.com/1741-7015/4/22
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according to European databases. The prevalence
increased substantially with age and was slightly higher in
men than in women, so that use was above 10% among
men over 65 years of age. These data agree well with other
studies from the UK and Spain that reported a prevalence
of regular aspirin use of 8–9% in elderly populations
[24,25].
In the US, according to the population-based National
Health and Nutrition Examination Survey (NHANES)
[26], close to 9% of adults were using an aspirin contain-
ing product regularly in the 2000–2002 period, although
the prevalence of aspirin use was above 30% in men over
65 years of age. Similarly, a contemporaneous US survey
specifically designed to provide information on drug use
Sensitivity analysis Figure 4
Sensitivity analysis. Estimated excess number of upper gastrointestinal tract complications (UGIC) cases attributable to aspirin 
(measured as the incidence rate difference between users and non-users) stratified by prior ulcer history and age for male and 
females, assuming a range of relative risks for aspirin from 1.5 to 3.
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reported a prevalence of aspirin use that ranged from 10%
in women and men aged 18–44 years of age to 39% in
men over 65 [27]. The higher prevalence of aspirin use in
the US surveys might be due not only to actual differences
in aspirin use or aspirin users in the US and Europe, but
also to methodological aspects. For example, the Euro-
pean databases used for the current study included only
prescription aspirin, focused on single component prod-
ucts used for cardioprotection and were based on prospec-
tively recorded prescriptions; while the US surveys
included prescription and nonprescription aspirin used
regularly for any indication and both as single component
or as part of multiple component products, and were
based on subject recall. Of note, the lack of information
on over the counter aspirin use would have a limited
impact on this particular study as we were interested in
users of aspirin for cardioprotection, and i) most regular
aspirin users in the UK and Spain seek prescriptions in
order to benefit from the drug coverage offered by the uni-
versal medical care, and ii) even if we had missed a frac-
tion of cardioprotective aspirin users, those included in
our population would probably be representative in terms
of UGIC risks and, therefore, valid for the objectives of the
study.
The specific UGIC risk for a given person according to the
most relevant gastrointestinal risk factors can be calcu-
lated using the estimates provided in this paper. In addi-
tion, these estimates can be used to determine the
expected number of UGIC cases in a particular group of
individuals during a given period of time. For example,
our estimates of the incidence of UGIC in the control
groups of VIGOR [21], CLASS [22], and TARGET [23] tri-
als were strikingly close to the observed ones, despite the
distinct methodological characteristics of the trials.
This paper also provides estimates for the absolute impact
of aspirin treatment on persons with different underlying
UGIC risk profiles. The excess risk attributable to aspirin
in the general population has traditionally been suggested
to be around 1–2 cases per 1,000 patients treated with
low-dose aspirin per year [8]. However, this figure largely
applies to a middle-aged group of people with no prior
history of peptic ulcer and may substantially underesti-
mate the bleeding risk among aspirin users in a real-life
setting, where persons over 65 are precisely the group
most likely to be taking low-dose aspirin for its cardiopro-
tective properties. We estimated an overall excess risk of 5
cases per 1,000 aspirin users per year. Yet this is an average
figure; the excess risk varied in parallel to the baseline
UGIC incidence rate and ranged from less than 1 case to
over 10 extra cases per 1,000 aspirin users per year for
patients with low or high underlying gastrointestinal risk,
respectively.
Therefore, age, together with other major risk factors for
UGIC such as prior history of gastrointestinal ulcer, male
gender, or concomitant use of NSAIDs, should be consid-
ered when balancing the risks and benefits of low-dose
aspirin for a particular subgroup of patients. Estimates of
the absolute impact of aspirin treatment can assist
patients and health care providers in evaluating the mag-
nitude of the trade-offs involved in taking aspirin for a
particular individual. Nonetheless, the decision making
process will still face the challenge of weighing the bene-
fits against the potential harm. That is, the number of car-
diovascular events prevented cannot be directly compared
with the number of bleeding events caused, as they are
associated with different degrees of disability and mortal-
ity. Moreover, each person might weigh these beneficial
and harmful effects differently [11].
Some of the estimates for the distribution of gastrointesti-
nal risk factors among aspirin users presented in this arti-
cle were based on relatively small numbers and, therefore,
there is a level of uncertainty around them. Regarding the
effect estimates, although we assigned reliable relative
risks to each gastrointestinal risk factor (i.e., they were
based on pooled estimates with tied confidence intervals),
we had to make assumptions (e.g. that the relative risk for
aspirin is constant across certain groups with different
baseline UGIC risks) that, while reasonable based on cur-
rent knowledge, might be proven partly wrong in future
studies. For simplicity, we restricted the number of gas-
trointestinal risk factors to those with greatest potential
impact due to their high prevalence and/or relative risk;
Table 1: Application of upper gastrointestinal tract complications  (UGIC) risk estimations to the populations of patients included in 
the control groups (exposed to traditional  non-steroidal anti-inflammatory drugs) for the Vioxx Gastrointestinal Outcomes Research 
(VIGOR), Celecoxib Long-term  Arthritis Safety Study (CLASS), and Therapeutic Arthritis Research and Gastrointestinal Event Trial 
(TARGET) trials
Study Age mean Female % Ulcer History % Aspirin % Reported Incidence Per 
1,000 p-y
Estimated Incidence Per 
1,000 p-y
VIGOR [21] 58 80 7.8 0 8.6* 7.0
CLASS [22] 60 69 9.6 20 14.5 9.5
TARGET [23] 63 76 3.5 24 9.1 8.1
*Excluding 11 cases with gastrointestinal ulcer without apparent bleeding, obstruction, or perforation.BMC Medicine 2006, 4:22 http://www.biomedcentral.com/1741-7015/4/22
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less frequent (e.g. use of anticoagulants, other comorbid-
ities) and weaker (e.g. smoking or alcohol drinking) risk
factors for UGIC were not considered. Also, while infor-
mation on other risk factors such as Helicobacter pylori
infection or genetic predisposition is rarely available at
present, these and other markers will probably become
important determinants of a person UGIC risk in the
future. Similarly, we did not include other benefits of aspi-
rin treatment, such as the secondary prevention of serious
vascular events other than myocardial infarction [5,6] or
the potential reduction in the risk of colon cancer [28]
and cognitive decline in the elderly [29]; nor other poten-
tial areas of harm, such as the increased risk of hemor-
rhagic strokes [5,6] and uncomplicated peptic ulcers [30].
However, aspirin effects on the risks of myocardial infarc-
tion and UGIC are the most common, firmly established
and serious and, therefore, would probably drive the deci-
sions [12]. Finally, we did not discuss interventions that
might modify the balance, such as use of a proton pump
inhibitor.
Conclusion
The net impact of aspirin on the risk of UGIC for a given
person depends on the underlying gastrointestinal risk.
The clinical decision about placing a person into low-dose
aspirin for cardioprotection should consider not only the
cardiovascular but also the gastrointestinal risk factors for
each individual. This paper presents estimates of the
UGIC risk for aspirin users with a wide range of gastroin-
testinal risk profiles.
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